FeRx begins magnetic drug-delivery trial:
This article was originally published in Clinica
Executive Summary
FeRx has begun a clinical trial to investigate the use of its magnetic targeted carrier (MTC) drug-delivery technology for the treatment of metastatic liver cancer. The trial of the company's MTC-DOX product will assess the MTC microparticles as a means of delivering a widely-used anti-cancer drug, doxorubicin. MTC-DOX is already being tested in clinical trials of patients with primary liver cancers, says the San Diego, California company. MTC microparticles are composed of elemental iron and activated carbon and can be directed to specific sites in the body using an externally applied magnetic field.